Title:A Pan-cancer Analysis Reveals the Abnormal Expression and Drug Sensitivity of CSF1
Volume: 22
Issue: 7
Author(s): Xiaoshuo Dai, Xinhuan Chen, Wei Chen, Yihuan Chen, Jun Zhao, Qiushuang Zhang and Jing Lu*
Affiliation:
- Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan Province 450001,
P.R. China
- Collaborative Innovation Center of Henan Province for Cancer Chemoprevention, Zhengzhou University, Zhengzhou,
Henan Province 450001, P.R. China
- State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University,
Zhengzhou, Henan Province 450052, P.R. China
Keywords:
CSF1, pan-cancer, mutation, DNA methylation, immune infiltration, drug sensitivity.
Abstract: Background: Colony-stimulating factor-1 (CSF1) is a cytokine that is closely related to normal
organ growth and development as well as tumor progression.
Objective: We aimed to summarize and clarify the reasons for the abnormal expression of CSF1 in tumors and
explore the role of CSF1 in tumor progression. Furthermore, drug response analysis could provide a reference
for clinical medication.
Methods: The expression of CSF1 was analyzed by TCGA and CCLE. Besides, cBioPortal and MethSurv databases
were used to conduct mutation and DNA methylation analyses. Further, correlations between CSF1 expression
and tumor stage, survival, immune infiltration, drug sensitivity and enrichment analyses were validated
via UALCAN, Kaplan-Meier plotter, TIMER, CTRP and Coexperia databases.
Results: CSF1 is expressed in a variety of tissues; meaningfully, it can be detected in the blood. Compared with
normal tissues, CSF1 expression was significantly decreased in most tumors. The missense mutation and DNA
methylation of CSF1 might cause the downregulated expression. Moreover, decreased CSF1 expression was
related to higher tumor stage and worse survival. Further, the promoter DNA methylation level of CSF1 was
prognostically significant in most tumors. Besides, CSF1 was closely related to immune infiltration, especially
macrophages. Importantly, CSF1 expression was associated with a good response to VEGFRs inhibitors, which
may be due to the possible involvement of CSF1 in tumor angiogenesis and metastasis processes.
Conclusion: The abnormal expression of CSF1 could serve as a promising biomarker of tumor progression and
prognosis in pan-cancer. Significantly, angiogenesis and metastasis inhibitors may show a good response to
CSF1-related tumors.